A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

  • Paolo Cameli | paolocameli88@gmail.com Respiratory Diseases Unit, Department of Medical and Surgical Sciences and Neurosciences, University of Siena, Italy. https://orcid.org/0000-0001-8639-2882
  • Miriana d'Alessandro Respiratory Diseases Unit, Department of Medical and Surgical Sciences and Neurosciences, University of Siena, Italy. https://orcid.org/0000-0002-2368-5722
  • Laura Bergantini Respiratory Diseases Unit, Department of Medical and Surgical Sciences and Neurosciences, University of Siena, Italy.
  • Elena Silvestri Interdisciplinary Internal Medicine, Department of Experimental and Clinical Medicine, University of Florence, Italy.
  • Arianna Romaldi Immunology and Cell Therapies Unit, Department of Experimental and Clinical Medicine, University of Florence, Italy. https://orcid.org/0000-0002-3455-1447
  • Giacomo Emmi Interdisciplinary Internal Medicine, Department of Experimental and Clinical Medicine, University of Florence, Italy.
  • Paola Parronchi Immunology and Cell Therapies Unit, Department of Experimental and Clinical Medicine, University of Florence, Italy. https://orcid.org/0000-0002-9184-5089
  • Elena Bargagli Respiratory Diseases Unit, Department of Medical and Surgical Sciences and Neurosciences, University of Siena, Italy.

Abstract

Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the effectiveness of omalizumab in a multicentre group of patients with Samter’s triad. We retrospectively enrolled eight patients (5 females) with Samter’s triad who underwent at least one year of omalizumab therapy. Clinical data, functional parameters and questionnaires for asthma and nasal polyposis control were collected at baseline and follow-up.  We observed a significant reduction of moderate-to-severe asthma exacerbations, together with an increase of FEV1 and a reduction of steroids intake. An improvement in asthma control and nasal symptoms was also reported. This multicenter study confirms the effectiveness of omalizumab in patients affected by Samter’s triad. Omalizumab may represent a potential therapeutic option for the management of this disease. 

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-08-06
Info
Issue
Section
Pneumology - Original Articles
Keywords:
Omalizumab, Samter’s triad, aspirin intolerance, anti-IgE, nasal polyposis
Statistics
  • Abstract views: 111

  • PDF: 75
How to Cite
Cameli, P., d’Alessandro, M., Bergantini, L., Silvestri, E., Romaldi, A., Emmi, G., Parronchi, P., & Bargagli, E. (2020). A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad. Monaldi Archives for Chest Disease, 90(3). https://doi.org/10.4081/monaldi.2020.1397